Melior Pharmaceuticals I, Inc.;Board Of Supervisors Of Louisiana State University
发明人:
REAUME, Andrew G.,CONG, Weina,GREENWAY, Frank,COULTER, Ann
申请号：
EP18783870
公开号：
EP3609500A4
申请日:
2018.04.09
申请国别(地区):
EP
年份:
2020
代理人:
摘要：
The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels； treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes； treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis； inducing the beiging of adipocytes； and preventing pancreatic beta cell degeneration.
